Extremely Long-Lasting B-cell Depletion and BAFFling Effects Following Obinutuzumab-Based Regimen in Lupus Nephritis

Extremely Long-Lasting B-cell Depletion and BAFFling Effects Following Obinutuzumab-Based Regimen in Lupus Nephritis

Saved in:

Bibliographic Details
Main Authors:	Dario Roccatello, Savino Sciascia, Emanuele De Simone, Thomas Schindler, Elsa Martins, Huiyan (Ashley) Mao, Daniela Rossi, Roberta Fenoglio
Format:	Article
Language:	English
Published:	Elsevier 2024-10-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924018801
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-3676 RESULTS FROM THE REGENCY TRIAL ASSESSING EFFICACY AND SAFETY OF OBINUTUZUMAB IN ACTIVE LUPUS NEPHRITIS
by: Brad Rovin, et al.
Published: (2025-02-01)

The Evolution of Crescents in Lupus Nephritis
by: Ana Malvar, et al.
Published: (2025-05-01)

Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis
by: Robert Nee, et al.
Published: (2015-01-01)

WCN24-1455 NOT EVERYTHING IN LUPUS IS LUPUS NEPHRITIS
by: Enrique Fleuvier Morales López, et al.
Published: (2024-04-01)

Gender Differences in the Pathogenesis and Outcome of Lupus and of Lupus Nephritis
by: Julie Schwartzman-Morris, et al.
Published: (2012-01-01)

Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01)

Evaluation of Treatment Response in Lupus Nephritis
by: Anca BOBIRCA, et al.
Published: (2021-12-01)

Recent advances in the treatment of lupus nephritis
by: Wan-xing Li, et al.
Published: (2022-08-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01)

The impacts of gender differences on systemic lupus erythematosus and lupus nephritis
by: LI Chun-hong, et al.
Published: (2019-01-01)

Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: outcomes at a tertiary care centre in Lahore, Pakistan
by: Muhammad Ahmed Saeed, et al.
Published: (2024-04-01)

Immune Checkpoint Therapy–Induced Lupus Nephritis
by: Imran Humza Hanif, et al.
Published: (2024-05-01)

Lupus nephritis: What new is in morphological diagnosis?
by: S G Radenska-Lopovok
Published: (2008-08-01)

Lupus Nephritis: 10 questions to think about
by: Enrique Morales, et al.
Published: (2025-02-01)

Chemokines and Chemokine Receptors in the Development of Lupus Nephritis
by: Xiaofeng Liao, et al.
Published: (2016-01-01)

Lupus nephritis and thrombotic microangiopathy: A review
by: Larisa A. Bobrova, et al.
Published: (2024-01-01)

Prediction of prognosis and renal outcome in lupus nephritis
by: Farah Tamirou, et al.
Published: (2020-10-01)

Disseminated Strongyloidiasis in a Patient With Lupus Nephritis
by: Muhammad Abu-Rmaileh, et al.
Published: (2023-09-01)

MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis
by: Cristen B. Chafin, et al.
Published: (2013-01-01)

Renal biopsy in lupus nephritis: To do or not to do?
by: Manish Rathi, et al.
Published: (2017-01-01)

Clinical significance of urine hepcidin in lupus nephritis
by: TANG Dai-rong, et al.
Published: (2017-01-01)

B cells and treatment progression in lupus nephritis
by: ZHANG Yue-qi, et al.
Published: (2019-01-01)

Research advances of the role of T lymphocytes in lupus nephritis
by: Zhang Ling-ge, et al.
Published: (2022-03-01)

Ras-MAPK pathway in patients with lupus nephritis
by: Dandan Liang, et al.
Published: (2025-03-01)

The Efficacy of Induction Treatment with a Cyclophosphamide- or Mycophenolate Mofetil-Based Regimen for Active Lupus Nephritis in Thailand: A Retrospective Cohort Study
by: Panuvich Poungsuwan, et al.
Published: (2025-02-01)

The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target
by: Emanuele Parodi, et al.
Published: (2025-02-01)

Lupus nephritis as a specific clinical and immunological phenotype of systemic lupus erythematosus
by: E. A. Aseeva, et al.
Published: (2022-12-01)

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India
by: V Jayaprakash, et al.
Published: (2020-01-01)

The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil
by: Teng Fong Ng, et al.
Published: (2020-01-01)

Lupus Nephritis in a Patient with Sickle Cell Disease
by: Vinay Minocha, et al.
Published: (2013-01-01)

Soluble Fas and the −670 Polymorphism of Fas in Lupus Nephritis
by: Juan José Bollain-y-Goytia, et al.
Published: (2014-01-01)

Correlation between dyslipidemia and disease activity of lupus nephritis
by: Hu Hong-tu, et al.
Published: (2021-01-01)

FDA approves belimumab for treatment of children with lupus nephritis
by: article Editorial
Published: (2022-10-01)

TNIP1/ABIN1 and lupus nephritis: review
by: Makayla P Brady, et al.
Published: (2020-10-01)

Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01)

Determination of nutrition index and correlation with activity of lupus nephritis
by: Rabrenović Violeta, et al.
Published: (2024-01-01)

Bioinformatics analysis of gene expression microarray in lupus nephritis
by: JIANG Qiu-zhu, et al.
Published: (2020-01-01)

One case of lupus nephritis with podocyticin folding glomerulopathy
by: Xu Liang, et al.
Published: (2021-01-01)

Single-cell RNA sequencing for the study of lupus nephritis
by: Jill Buyon, et al.
Published: (2019-12-01)